RESEARCH TRIANGLE PARK – AskBio, a rapidly growing Triangle gene therapy company that earlier this year raised $235 million from investors, is adding nanotechnology to its arsenal of products and services.

On Tuesday,  Asklepios BioPharmaceutical – the full name of AskBio – said it had acquired all assets of RoverMed, which has developed a nano-tech based “cargo delivery” technology for treatments.

Financial terms were not disclosed.

RoverMed, which was venture capital backed and based in St. Cloud Minnesota, had rasied some $2.2 million in capital. according to CrunchBase.

AskBio says the RoverMed technology enables “delivery of therapeutics into the nucleus of diseased cells without affecting healthy cells.”

This video describes the process:

RoverMed Targeted Delivery System

RoverMed's targeted delivery system enables the drug to reach challenging disease sites, make therapeutic success for the next generation of drugs for unmet patient needs!

Posted by RoverMed on Friday, September 22, 2017

“The addition of RoverMed technology provides us with another means for delivering therapeutic molecules, including large or small molecules, to increase stability and specificity and could enable entire new tissues and diseases to be reachable,” said Sheila Mikhail, CEO of AskBio, in the annoucement. “We continue to explore new technologies and expand therapeutic innovation to ensure that effective gene therapies for genetic disorders can be accessible to patients in need across the globe without limits.”

The deal is one of several made by AskBio since raising its new funding.

Recent AskBio headlines in WRAL TechWire:

RTP-based AskBio expands gene therapy target list with acquisition of Scottish biotech

AskBio forms gene therapy alliance with Selecta Biosciences

AskBio gets $235 million in gene therapy support